Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tc 99m Tilmanocept Imaging vs Histology in RA
NCT04078191Phase 2Terminated
- Sponsor
- Navidea Biopharmaceuticals, Inc.
- Start
- Sep 2021
- Primary completion
- Jul 2024
- Modality
- Radiopharmaceutical, Biologic
- Countries
- 2
01
Overview
A Phase 2 trial of technetium tc 99m tilmanocept in rheumatoid arthritis (RA), sponsored by Navidea Biopharmaceuticals, Inc.. Started Sep 2021; status: terminated.
02
Drugs
technetium tc 99m tilmanocept
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT04078191.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04078191.